Insider Selling: uniQure (NASDAQ:QURE) Director Sells 5,295 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 5,295 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $42.57, for a total value of $225,408.15. Following the sale, the director directly owned 25,996 shares in the company, valued at $1,106,649.72. This trade represents a 16.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total value of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The shares were sold at an average price of $30.01, for a total transaction of $79,376.45.

uniQure Price Performance

QURE stock opened at $46.29 on Monday. The stock has a market cap of $2.92 billion, a P/E ratio of -13.30 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company’s 50 day moving average is $24.74 and its two-hundred day moving average is $22.17.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. Research analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. Torren Management LLC acquired a new stake in uniQure during the 4th quarter valued at $28,000. Jones Financial Companies Lllp lifted its stake in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure in the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC bought a new position in shares of uniQure during the fourth quarter valued at approximately $48,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in uniQure in the third quarter worth $50,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on QURE shares. Leerink Partners lifted their target price on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Barclays raised shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $25.00 to $65.00 in a report on Thursday. Wolfe Research assumed coverage on uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Finally, Sanford C. Bernstein cut uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $58.92.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.